InvestSMART

Anteris Technologies Ltd (ASX:AVR)

ALERT: Price-sensitive ASX Announcement for AVR
Current share price for AVR : $11.370 -1.54 (-11.93%)+
Announcement
Release
25 May 2026 8:53AM
Price at Release
$12.910
Full Release
download
Summary
Anteris Technologies Global Corp., a company listed on NASDAQ and ASX under the symbol AVR, has filed a prospectus supplement and Form 8-K with the SEC to establish an at-the-market equity offering under Rule 415 of the U.S. Securities Act of 1933. The company, which specializes in structural heart medical devices, aims to raise up to $250 million through this equity offering, facilitated by a Sales Agreement with TD Securities. The lead product, DurAVR Transcatheter Heart Valve, is designed to treat aortic stenosis and utilizes the company's patented anti-calcification ADAPT tissue technology. The offering will be conducted via NASDAQ with TD Cowen as the acting agent.
Key Points
  • Anteris Technologies is conducting an 'at-the-market' equity offering.
  • The offering is facilitated by a Sales Agreement with TD Securities (TD Cowen).
  • The prospectus supplement and Form 8-K were filed on May 22, 2026.
  • The offering aims to raise up to $250 million.
  • Anteris' lead product is the DurAVR Transcatheter Heart Valve.
  • DurAVR is designed to replicate normal aortic blood flow using ADAPT tissue technology.
  • The company's headquarters are in Toowong, Australia, with a significant presence in Minneapolis, USA.
  • Anteris is listed on both NASDAQ and the Australian Securities Exchange under the symbol AVR.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.